|
Dr. Miller joined Kémia as Senior Director of Biology in September, 2002 and is responsible for characterizing the in vitro and in vivo pharmacology of compounds advancing through Kémia's internal programs. Prior to joining Kémia, Dr. Miller was Director of the Department of New Lead Discovery at Ligand Pharmaceuticals. During eight years at Ligand, his group played a critical role in the discovery and lead optimization of fifteen NCEs that entered development for a variety of therapeutic indications, including ten compounds currently in Phase I through Phase III clinical trials. Prior to Ligand, Dr. Miller worked at Parnassus Pharmaceuticals where he built the cellular and molecular biology team. His initial industry experience was at Amgen where he utilized molecular approaches to identify novel growth factor receptors and ligands involved in hematopoiesis and angiogenesis. Dr. Miller received his Ph.D. from Caltech and was a Helen Hay Whitney postdoctoral fellow at the University of California, Berkeley. | 